Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition between biotech giants, and this makes investors confuse to predict which stock will be more fruitful for them in terms of revenue. But one should not ignore the fact that other diseases and medical challenges still exist even if they are not like that much popular as the COVID-19 is.
Moderna Inc (NASDAQ: MRNA)
Moderna, Inc. (MRNA) is a leading mRNA Technology platform that aims on using messenger RNA (mRNA) to produce a new generation of transformative drugs for patients.
2020 proved to be a good year for Moderna because its share price has reached up to the mark of more than 500%.Covid-19 mRNA-1273 is mainly responsible for this rise as this vaccine has shown very effective results. Further this vaccine has gained the trust of about 30 countries’ regulatory bodies as they have approved it for use.
According to MichaelYee, a Wall Street analyst, Moderna has already signed $11.7B in contracts in which dose range is from 510M to 525M. The company is looking forward to signing additional contracts for 2021 and 2022 where the capacity will reach up to 1.2B doses.
Moderna has to compete with its competitors especially Pfizer and JNJ(which is going to share results 3rd trial phase of Covid-19 Vaccine shortly) to maintain its reputation but due to the very high demand for vaccine in the globe, at least five companies can sell at full capacity to fulfill the need of vaccine in the globe. Moderna has also stepped in the 2nd phase study of the age group from 12 to 17 and U.S. Food and Drug may authorize vaccine for teens which could add more value to Moderna’sannual revenue.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
Vertex Pharmaceutics Inc.(VRTX) is focused on discovering, developing & manufacturing small molecule drugs for the cure of cystic fibrosis, viral infections, bacterial infections, autoimmune diseases, cancer, and neurological disorders.
The company is playing the lead role in the cure of cystic fibrosis as it is estimated that 50% of patients diagnosed with cystic fibrosis in many countries are using Vertex’s medications. Vertex’s main product is Trikafta which is approved by the FDA at the end of 2019. Trikafta has already generated $3b revenue alone and is expected to generate more in the future as the company is putting serious effort to get the approval of this product for different age groups.
Novavax, Inc. (NASDAQ: NVAX)
Novavax, Inc. (NVAX) is a late-stage company that aims in improved global health through the discovery, development, and commercialization of innovative vaccines to prevent infectious disease. The company’s main contributions in preventing diseases include COVID-19, seasonal influenza, RSV, Ebola, Mers, and SARS.
The company has recently announced that it has contracted with the Government of Canada to supply 76Million doses of NVX-CoV2373, a company’s recombinant protein-based COVID-19 vaccine, to control the pandemic in the region. This contract will help the company to generate a handsome revenue in future.
Besides the COVID-19 vaccine, the company is putting some serious effort into Nanoflu, a seasonal influenza vaccine for the olders, to influence the global influenza market which will worth more than 6Billion annually by 2026. The 3rd clinical analysis of the Nanoflu showed exceptional results and now the company is expecting to get approval from the U.S food and drug administration soon to commercialize its product and if it happens, it will further boost the company’s reputation and maximize the potential to generate billions of dollars revenue annually.